USFDA hits Jubilant's Montreal plant with a Warning Letter
The FDA found prior remediation efforts insufficient, escalating the site from 'Official Action Indicated' status. New drug approvals from the facility are now frozen.
— 9 earlier stories on Jubilant Pharmova Ltd. →What's new
- Jubilant Pharmova's Montreal subsidiary got a USFDA Warning Letter after a late-2025 inspection.
- The letter escalates the site from prior 'Official Action Indicated' status, meaning earlier fixes didn't satisfy inspectors.
- The facility makes sterile injectables and ophthalmic solutions; it was already posting operational losses.
Why this matters
A Warning Letter is a hard stop on new approvals from a site. For Jubilant's contract-manufacturing segment, which management had pegged for growth, this freezes the pipeline from a key asset. The Kirkland plant now carries unresolved regulatory risk, and the operational turnaround just got harder.
What we're watching
- The timeline and cost of the remediation required to clear the Warning Letter.
- Any impact on existing product supply or export licenses from the site.
- Whether Jubilant shifts contract-manufacturing capacity to other facilities.
The full read
Jubilant Pharmova's Montreal manufacturing site just hit a wall. The USFDA issued a Warning Letter after a late-2025 inspection, escalating the facility from a prior 'Official Action Indicated' status. That means the company's earlier attempts to fix compliance issues fell short. The Kirkland plant, which makes sterile injectables and ophthalmic solutions, is now frozen out of new drug approvals until it clears the letter. This is the site's second regulatory strike. The first one came after inspections flagged problems; this one says the fixes didn't work. For Jubilant's contract-manufacturing business, which management had flagged for growth, the pipeline from a key asset just stalled. The plant was already losing money last fiscal year. Now it carries unresolved regulatory risk on top of operational losses. Clearing a Warning Letter is expensive and slow, and the FDA's clock doesn't start until the company proves its remediation is complete.
Questions answered
- What does the Warning Letter actually do to Jubilant's Montreal operations?
- It freezes the site's ability to get new product approvals from the USFDA until compliance issues are resolved. Existing operations continue under enhanced controls, but the pipeline is blocked.
- How did the site get to this point?
- The Montreal facility was already under 'Official Action Indicated' status after earlier inspections. The Warning Letter means the FDA reviewed the company's subsequent remediation efforts and found them insufficient.
- Why is this particular site important to Jubilant?
- The Kirkland plant specializes in sterile injectables and ophthalmic solutions, key products in Jubilant's contract-manufacturing (CDMO) portfolio. Management had recently highlighted that segment's growth potential.
- What's the financial exposure here?
- The site was already reporting operational losses in the previous fiscal year. The Warning Letter delays any turnaround and adds regulatory risk that could restrict exports if not resolved.
Jubilant Pharmova Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLPHARMA →- 29 May 2026 · 9:53 PM IST USFDA hits Jubilant's Montreal plant with a Warning Letter
- 6d ago Jubilant Pharmova's ₹53.37 cr tax setback
- 12d ago Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
- 17d ago Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
- 45d ago Jubilant Pharmova subsidiary lands ₹107.89 cr tax demand